Updated hemovigilance data do not show an increased risk of allergic reactions to methylene blue–treated plasma

The authors speculate that an allergic risk might emanate from the pathogen inactivation process itself by causing alterations of the plasma during the MB/light treatment and filtration steps that are part of the THERAFLEX MB-Plasma process (MacoPharma, Tourcoing, France). [...]FFP-MB was introduced in France in 2008, and relevant numbers of FFP-MB units were used in 2009 for the first time.2 These imbalances in use between the different types of FFP limit the validity of comparative analysis of the frequency of rare adverse events.